Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum‐Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA Study

Ähnliche Einträge

• Clinical Features and Risk Factors of Enfortumab Vedotin–Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study ( YUSHIMA Study)
  von: Takahiko Soma, et al.
  Veröffentlicht: (2025)
• Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First‐Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real‐World Study ( YUSHIMA Study)
  von: Rie Muta, et al.
  Veröffentlicht: (2026)
• Real‐World Outcomes of First‐Line Systematic Treatment in Locally Advanced or Metastatic Upper Urinary Tract Urothelial Carcinoma With Renal Impairment ( YUSHIMA Study)
  von: Tomoki Kimura, et al.
  Veröffentlicht: (2025)
• Real‐World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: A Propensity‐Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis
  von: Yosuke Yasuda, et al.
  Veröffentlicht: (2026)
• Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone‐Sensitive Prostate Cancer: YUSHIMA Study
  von: Yosuke Yasuda, et al.
  Veröffentlicht: (2025)